Many have repeatedly stated that IPIX and/or Degrado should have "designed" the trial differently. Unless I'm badly mistaken, IV was the only available dosing mechanism at the time. How many "mild to moderate" patients would have participated in such a dosing regimen? And how involved was the FDA? It really seems to me that IPIX was fortunate to get the trial, and the "other" testing, done at all given the current pandemic situation. More information should be forthcoming.